TroFuse-031NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 31 versions: 30 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 111 → 117 locations
- Minor Study sites: 111 to 113
- Minor Trial sites expanded: 107 → 111 locations
- Minor Trial sites expanded: 104 → 107 locations
- Minor Study sites: 104 to 105
- Minor Trial sites expanded: 95 → 104 locations
- Minor Study sites: 94 to 95
- Notable Eligibility criteria expanded, about 30 words
- Trial sites expanded: 91 → 94 locations
- Secondary endpoints: details revised at 11 of 11 entries
- Minor Study sites: 90 to 91v23
- Minor Trial sites expanded: 86 → 90 locationsv22
- Minor Trial sites expanded: 82 → 86 locationsv21
- Minor Study sites: 80 to 82v20
- Minor Study sites: 79 to 80v19
- Minor Trial sites expanded: 73 → 79 locationsv18
- Minor Study sites: 71 to 73v17
- Minor Study sites: 69 to 71v16
- Minor Study sites: 67 to 69v15
- Minor Study sites: 65 to 67v14
- Minor Study sites: 63 to 65v13
- Notable Eligibility criteria expanded, about 15 words
- Trial sites expanded: 50 → 63 locations
- Minor Trial sites expanded: 42 → 50 locationsv11
- Minor Trial sites expanded: 38 → 42 locationsv10
- Minor Trial sites expanded: 30 → 38 locationsv9
- Minor Trial sites expanded: 27 → 30 locationsv8
- Minor Trial sites expanded: 21 → 27 locationsv7
- Minor Trial sites expanded: 3 → 21 locations
- Start date changed from estimate of Apr 30, 2026 to Apr 23, 2026
- Minor Start date: Apr 15, 2026 to Apr 30, 2026v4
- Minor Study sites: 2 to 3v3
- Notable Recruitment opened
- Study sites: 0 to 2
- Start date: Mar 17, 2026 to Apr 15, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Participants receive 4 mg/kg of sacituzumab tirumotecan every 2 weeks (Q2W) via intravenous (IV) infusion until disease progression or unacceptable toxicity.
Participants receive paclitaxel 175 mg/m\^2, docetaxel 75 mg/m\^2, or vinflunine 320 mg/m\^2 IV every 3 weeks (Q3W), at the investigator's discretion, until disease progression or unacceptable toxicity.
Biologicals: Sacituzumab tirumotecan
Drugs: Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy
Sites
117 sites in 17 countries
United States 23, China 20, Japan 16, Italy 9, Spain 8, Netherlands 7, Greece 5, Israel 5, Argentina 4, Belgium 4, Brazil 4, Canada 3, Australia 2, France 2, Sweden 2, United Kingdom 2, Germany 1